JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Circulating Plasma Exosomal PD-L1 Predicts Prognosis of Head and Neck Squamous Cell Carcinoma After Radiation Therapy

  • 0Department of Radiation Oncology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Advances in Radiation Oncology +

|

February 26, 2024

|

February 26, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

Pretreatment exosomal programmed death-ligand 1 (PD-L1) in plasma predicts outcomes for head and neck squamous cell carcinoma (HNSCC) patients undergoing radiation therapy. High exosomal PD-L1 levels correlate with poorer progression-free survival and local control.

Area Of Science

  • Oncology
  • Immunotherapy
  • Biomarker Discovery

Background

  • Radiation therapy is a standard treatment for head and neck squamous cell carcinoma (HNSCC).
  • Predictive biomarkers are crucial for optimizing HNSCC treatment strategies.
  • Programmed death-ligand 1 (PD-L1) is an immune checkpoint protein implicated in cancer progression.

Purpose Of The Study

  • To investigate the association between circulating plasma programmed death-ligand 1 (PD-L1) levels and treatment outcomes in HNSCC patients receiving radiation therapy.
  • To determine if pretreatment PD-L1, both total and exosomal, can serve as a prognostic biomarker for HNSCC patients.

Main Methods

  • Retrospective analysis of plasma samples from 76 HNSCC patients before radiation therapy.
  • Quantification of total and exosomal PD-L1 using enzyme-linked immunosorbent assay.
  • Statistical analysis including univariate and multivariate models to assess the correlation between PD-L1 levels and overall survival (OS), progression-free survival (PFS), and local control (LC).

Main Results

  • Median total PD-L1 was 115.1 pg/mL; median exosomal PD-L1 was 2.8 pg/mL.
  • Elevated pretreatment exosomal PD-L1 was significantly associated with poorer PFS and LC.
  • 1-year PFS was 79.2% for high exosomal PD-L1 vs. 33.3% for low (P < .001).
  • 1-year LC was 87.3% for high exosomal PD-L1 vs. 50.0% for low (P < .001).
  • Total PD-L1 and exosomal PD-L1 did not significantly impact OS.

Conclusions

  • Pretreatment circulating exosomal PD-L1 in plasma is a significant prognostic factor for HNSCC patients undergoing radiation therapy.
  • Exosomal PD-L1 levels can help predict progression-free survival and local control.
  • This finding supports the potential utility of exosomal PD-L1 as a predictive biomarker in HNSCC management.